Mega Lifesciences PCL (BKK:MEGA)

Mega Lifesciences PCL Balance Sheet

Financials in millions THB. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3,652	4,273	3,463	2,357	2,453	2,198
Short-Term Investments	355.97	370.96	395.19	365.05	345.55	342.64
Cash & Short-Term Investments	4,008	4,644	3,858	2,722	2,799	2,540
Cash Growth	8.07%	20.37%	41.74%	-2.76%	10.18%	106.14%
Accounts Receivable	3,471	3,306	2,975	3,314	3,107	2,557
Other Receivables	306.78	143.66	152.53	158.28	180.15	164.18
Receivables	3,777	3,450	3,128	3,472	3,287	2,721
Inventory	3,606	3,038	3,033	3,377	4,109	3,823
Prepaid Expenses	-	58.79	60.43	58.59	60.14	53.43
Other Current Assets	140.51	162.24	147.7	360.23	334.95	162.8
Total Current Assets	11,532	11,353	10,227	9,990	10,590	9,301
Property, Plant & Equipment	2,389	2,409	2,213	2,225	2,151	2,103
Long-Term Investments	-	37.22	40.39	221.15	222.88	214.79
Goodwill	437.89	428.51	449	456.24	465.88	476.25
Other Intangible Assets	878.81	867.17	869.72	862.23	863.31	876.89
Long-Term Deferred Tax Assets	390.48	375.3	299.89	278.95	250.32	210.41
Other Long-Term Assets	398.04	289.03	111.52	81	103.49	89.75
Total Assets	16,026	15,759	14,210	14,115	14,646	13,272

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2,005	1,720	1,685	1,925	2,793	2,527
Accrued Expenses	878.12	1,096	1,102	1,140	1,604	1,283
Short-Term Debt	520.29	472.24	287.58	76	229.18	168.18
Current Portion of Leases	59.31	65.1	63.83	43.78	82.96	56.21
Current Income Taxes Payable	340.18	323.29	145.54	108.45	204.18	185.86
Other Current Liabilities	1,442	1,419	630.65	1,133	624.44	633.02
Total Current Liabilities	5,245	5,096	3,914	4,427	5,538	4,853
Long-Term Leases	115.15	146.2	139.83	132.06	108.73	131.94
Pension & Post-Retirement Benefits	322.63	300.98	278.11	251.91	222.94	261.28
Long-Term Deferred Tax Liabilities	0.05	0.6	1.05	2.14	-	-
Total Liabilities	5,682	5,544	4,333	4,813	5,870	5,247

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	435.94	435.94	435.94	435.94	435.94	435.94
Additional Paid-In Capital	2,305	2,305	2,305	2,305	2,305	2,305
Retained Earnings	8,736	8,353	7,830	7,210	6,655	5,766
Comprehensive Income & Other	-1,132	-878.11	-693.31	-648.11	-618.9	-503.97
Total Common Equity	10,344	10,215	9,877	9,302	8,777	8,003
Minority Interest	0.04	0.03	0.08	0.02	0.07	22.3
Shareholders' Equity	10,344	10,215	9,877	9,302	8,777	8,025
Total Liabilities & Equity	16,026	15,759	14,210	14,115	14,646	13,272

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	694.75	683.54	491.24	251.84	420.87	356.33
Net Cash (Debt)	3,313	3,960	3,367	2,470	2,378	2,184
Net Cash Growth	8.00%	17.63%	36.31%	3.86%	8.89%	273.44%
Net Cash Per Share	3.80	4.54	3.86	2.83	2.73	2.50
Filing Date Shares Outstanding	871.87	871.87	871.87	871.87	871.87	871.87
Total Common Shares Outstanding	871.87	871.87	871.87	871.87	871.87	871.87
Working Capital	6,287	6,256	6,312	5,563	5,052	4,448
Book Value Per Share	11.86	11.72	11.33	10.67	10.07	9.18
Tangible Book Value	9,027	8,920	8,558	7,984	7,447	6,650
Tangible Book Value Per Share	10.35	10.23	9.82	9.16	8.54	7.63

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 29, 2026

Data Sources Report a data error